nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—UGT1A9—Irinotecan—lung cancer	0.145	0.281	CbGbCtD
Tapentadol—CYP2C19—Gefitinib—lung cancer	0.0545	0.106	CbGbCtD
Tapentadol—CYP2C19—Teniposide—lung cancer	0.0529	0.103	CbGbCtD
Tapentadol—CYP2C9—Gefitinib—lung cancer	0.0453	0.0879	CbGbCtD
Tapentadol—CYP2C9—Teniposide—lung cancer	0.0439	0.0853	CbGbCtD
Tapentadol—CYP2D6—Gefitinib—lung cancer	0.0414	0.0804	CbGbCtD
Tapentadol—CYP2D6—Vinorelbine—lung cancer	0.0319	0.0619	CbGbCtD
Tapentadol—CYP2C9—Paclitaxel—lung cancer	0.0245	0.0476	CbGbCtD
Tapentadol—CYP2D6—Erlotinib—lung cancer	0.0245	0.0475	CbGbCtD
Tapentadol—CYP2C9—Cisplatin—lung cancer	0.0197	0.0383	CbGbCtD
Tapentadol—CYP2D6—Vinblastine—lung cancer	0.0197	0.0382	CbGbCtD
Tapentadol—CYP2D6—Doxorubicin—lung cancer	0.0121	0.0235	CbGbCtD
Tapentadol—Feeling abnormal—Irinotecan—lung cancer	0.00024	0.000825	CcSEcCtD
Tapentadol—Confusional state—Paclitaxel—lung cancer	0.000239	0.000823	CcSEcCtD
Tapentadol—Anaphylactic shock—Paclitaxel—lung cancer	0.000237	0.000816	CcSEcCtD
Tapentadol—Oedema—Paclitaxel—lung cancer	0.000237	0.000816	CcSEcCtD
Tapentadol—Paraesthesia—Cisplatin—lung cancer	0.000237	0.000816	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Methotrexate—lung cancer	0.000237	0.000815	CcSEcCtD
Tapentadol—Tachycardia—Etoposide—lung cancer	0.000236	0.000813	CcSEcCtD
Tapentadol—Infection—Paclitaxel—lung cancer	0.000236	0.000811	CcSEcCtD
Tapentadol—Dyspnoea—Cisplatin—lung cancer	0.000236	0.00081	CcSEcCtD
Tapentadol—Skin disorder—Etoposide—lung cancer	0.000235	0.000809	CcSEcCtD
Tapentadol—Erectile dysfunction—Methotrexate—lung cancer	0.000235	0.000808	CcSEcCtD
Tapentadol—Hyperhidrosis—Etoposide—lung cancer	0.000234	0.000805	CcSEcCtD
Tapentadol—Feeling abnormal—Gemcitabine—lung cancer	0.000234	0.000804	CcSEcCtD
Tapentadol—Shock—Paclitaxel—lung cancer	0.000234	0.000803	CcSEcCtD
Tapentadol—Dizziness—Vinorelbine—lung cancer	0.000233	0.000803	CcSEcCtD
Tapentadol—Nervous system disorder—Paclitaxel—lung cancer	0.000233	0.000801	CcSEcCtD
Tapentadol—Tachycardia—Paclitaxel—lung cancer	0.000232	0.000797	CcSEcCtD
Tapentadol—Breast disorder—Doxorubicin—lung cancer	0.000231	0.000794	CcSEcCtD
Tapentadol—Skin disorder—Paclitaxel—lung cancer	0.000231	0.000793	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Doxorubicin—lung cancer	0.00023	0.000791	CcSEcCtD
Tapentadol—Decreased appetite—Cisplatin—lung cancer	0.00023	0.00079	CcSEcCtD
Tapentadol—Hyperhidrosis—Paclitaxel—lung cancer	0.000229	0.000789	CcSEcCtD
Tapentadol—Nasopharyngitis—Doxorubicin—lung cancer	0.000228	0.000786	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Cisplatin—lung cancer	0.000228	0.000785	CcSEcCtD
Tapentadol—Infestation NOS—Methotrexate—lung cancer	0.000227	0.000782	CcSEcCtD
Tapentadol—Infestation—Methotrexate—lung cancer	0.000227	0.000782	CcSEcCtD
Tapentadol—Depression—Methotrexate—lung cancer	0.000227	0.00078	CcSEcCtD
Tapentadol—Hypotension—Etoposide—lung cancer	0.000226	0.000778	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000225	0.000775	CcSEcCtD
Tapentadol—Vomiting—Vinorelbine—lung cancer	0.000224	0.000772	CcSEcCtD
Tapentadol—Rash—Vinorelbine—lung cancer	0.000223	0.000765	CcSEcCtD
Tapentadol—Dermatitis—Vinorelbine—lung cancer	0.000222	0.000765	CcSEcCtD
Tapentadol—Hypotension—Paclitaxel—lung cancer	0.000222	0.000763	CcSEcCtD
Tapentadol—Headache—Vinorelbine—lung cancer	0.000221	0.00076	CcSEcCtD
Tapentadol—Syncope—Docetaxel—lung cancer	0.000221	0.00076	CcSEcCtD
Tapentadol—Palpitations—Docetaxel—lung cancer	0.000218	0.000749	CcSEcCtD
Tapentadol—Feeling abnormal—Cisplatin—lung cancer	0.000218	0.000749	CcSEcCtD
Tapentadol—Paraesthesia—Etoposide—lung cancer	0.000217	0.000748	CcSEcCtD
Tapentadol—Loss of consciousness—Docetaxel—lung cancer	0.000217	0.000745	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000216	0.000744	CcSEcCtD
Tapentadol—Dyspnoea—Etoposide—lung cancer	0.000216	0.000742	CcSEcCtD
Tapentadol—Somnolence—Etoposide—lung cancer	0.000215	0.00074	CcSEcCtD
Tapentadol—Cough—Docetaxel—lung cancer	0.000215	0.00074	CcSEcCtD
Tapentadol—Insomnia—Paclitaxel—lung cancer	0.000215	0.000738	CcSEcCtD
Tapentadol—Hypersensitivity—Irinotecan—lung cancer	0.000214	0.000738	CcSEcCtD
Tapentadol—Convulsion—Docetaxel—lung cancer	0.000214	0.000735	CcSEcCtD
Tapentadol—Paraesthesia—Paclitaxel—lung cancer	0.000213	0.000733	CcSEcCtD
Tapentadol—Dyspnoea—Paclitaxel—lung cancer	0.000212	0.000728	CcSEcCtD
Tapentadol—Somnolence—Paclitaxel—lung cancer	0.000211	0.000726	CcSEcCtD
Tapentadol—Decreased appetite—Etoposide—lung cancer	0.00021	0.000724	CcSEcCtD
Tapentadol—Arthralgia—Docetaxel—lung cancer	0.00021	0.000722	CcSEcCtD
Tapentadol—Nausea—Vinorelbine—lung cancer	0.00021	0.000721	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Etoposide—lung cancer	0.000209	0.000719	CcSEcCtD
Tapentadol—Dyspepsia—Paclitaxel—lung cancer	0.000209	0.000719	CcSEcCtD
Tapentadol—Asthenia—Irinotecan—lung cancer	0.000209	0.000718	CcSEcCtD
Tapentadol—Fatigue—Etoposide—lung cancer	0.000209	0.000718	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000208	0.000717	CcSEcCtD
Tapentadol—Constipation—Etoposide—lung cancer	0.000207	0.000712	CcSEcCtD
Tapentadol—Decreased appetite—Paclitaxel—lung cancer	0.000206	0.00071	CcSEcCtD
Tapentadol—Dry mouth—Docetaxel—lung cancer	0.000205	0.000706	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Doxorubicin—lung cancer	0.000205	0.000706	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000205	0.000705	CcSEcCtD
Tapentadol—Fatigue—Paclitaxel—lung cancer	0.000205	0.000704	CcSEcCtD
Tapentadol—Pollakiuria—Doxorubicin—lung cancer	0.000204	0.000702	CcSEcCtD
Tapentadol—Asthenia—Gemcitabine—lung cancer	0.000203	0.0007	CcSEcCtD
Tapentadol—Constipation—Paclitaxel—lung cancer	0.000203	0.000698	CcSEcCtD
Tapentadol—Confusional state—Docetaxel—lung cancer	0.000203	0.000698	CcSEcCtD
Tapentadol—Urinary tract disorder—Methotrexate—lung cancer	0.000202	0.000693	CcSEcCtD
Tapentadol—Anaphylactic shock—Docetaxel—lung cancer	0.000201	0.000692	CcSEcCtD
Tapentadol—Oedema—Docetaxel—lung cancer	0.000201	0.000692	CcSEcCtD
Tapentadol—Pruritus—Gemcitabine—lung cancer	0.000201	0.00069	CcSEcCtD
Tapentadol—Urethral disorder—Methotrexate—lung cancer	0.0002	0.000688	CcSEcCtD
Tapentadol—Infection—Docetaxel—lung cancer	0.0002	0.000687	CcSEcCtD
Tapentadol—Weight decreased—Doxorubicin—lung cancer	0.0002	0.000687	CcSEcCtD
Tapentadol—Feeling abnormal—Etoposide—lung cancer	0.000199	0.000686	CcSEcCtD
Tapentadol—Diarrhoea—Irinotecan—lung cancer	0.000199	0.000685	CcSEcCtD
Tapentadol—Shock—Docetaxel—lung cancer	0.000198	0.000681	CcSEcCtD
Tapentadol—Nervous system disorder—Docetaxel—lung cancer	0.000197	0.000679	CcSEcCtD
Tapentadol—Infestation NOS—Doxorubicin—lung cancer	0.000197	0.000677	CcSEcCtD
Tapentadol—Infestation—Doxorubicin—lung cancer	0.000197	0.000677	CcSEcCtD
Tapentadol—Visual impairment—Methotrexate—lung cancer	0.000197	0.000677	CcSEcCtD
Tapentadol—Tachycardia—Docetaxel—lung cancer	0.000196	0.000675	CcSEcCtD
Tapentadol—Feeling abnormal—Paclitaxel—lung cancer	0.000196	0.000673	CcSEcCtD
Tapentadol—Skin disorder—Docetaxel—lung cancer	0.000195	0.000672	CcSEcCtD
Tapentadol—Hypersensitivity—Cisplatin—lung cancer	0.000195	0.00067	CcSEcCtD
Tapentadol—Diarrhoea—Gemcitabine—lung cancer	0.000194	0.000667	CcSEcCtD
Tapentadol—Dizziness—Irinotecan—lung cancer	0.000192	0.000662	CcSEcCtD
Tapentadol—Urticaria—Etoposide—lung cancer	0.000192	0.000661	CcSEcCtD
Tapentadol—Urinary tract infection—Doxorubicin—lung cancer	0.000191	0.000658	CcSEcCtD
Tapentadol—Eye disorder—Methotrexate—lung cancer	0.000191	0.000656	CcSEcCtD
Tapentadol—Asthenia—Cisplatin—lung cancer	0.00019	0.000652	CcSEcCtD
Tapentadol—Cardiac disorder—Methotrexate—lung cancer	0.000189	0.000652	CcSEcCtD
Tapentadol—Urticaria—Paclitaxel—lung cancer	0.000189	0.000649	CcSEcCtD
Tapentadol—Hypotension—Docetaxel—lung cancer	0.000188	0.000647	CcSEcCtD
Tapentadol—Angiopathy—Methotrexate—lung cancer	0.000185	0.000637	CcSEcCtD
Tapentadol—Vomiting—Irinotecan—lung cancer	0.000185	0.000636	CcSEcCtD
Tapentadol—Immune system disorder—Methotrexate—lung cancer	0.000184	0.000634	CcSEcCtD
Tapentadol—Mediastinal disorder—Methotrexate—lung cancer	0.000184	0.000633	CcSEcCtD
Tapentadol—Rash—Irinotecan—lung cancer	0.000184	0.000631	CcSEcCtD
Tapentadol—Dermatitis—Irinotecan—lung cancer	0.000183	0.000631	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000183	0.00063	CcSEcCtD
Tapentadol—Chills—Methotrexate—lung cancer	0.000183	0.00063	CcSEcCtD
Tapentadol—Headache—Irinotecan—lung cancer	0.000182	0.000627	CcSEcCtD
Tapentadol—Insomnia—Docetaxel—lung cancer	0.000182	0.000626	CcSEcCtD
Tapentadol—Diarrhoea—Cisplatin—lung cancer	0.000181	0.000622	CcSEcCtD
Tapentadol—Paraesthesia—Docetaxel—lung cancer	0.000181	0.000621	CcSEcCtD
Tapentadol—Vomiting—Gemcitabine—lung cancer	0.00018	0.00062	CcSEcCtD
Tapentadol—Bradycardia—Doxorubicin—lung cancer	0.00018	0.000619	CcSEcCtD
Tapentadol—Dyspnoea—Docetaxel—lung cancer	0.000179	0.000617	CcSEcCtD
Tapentadol—Somnolence—Docetaxel—lung cancer	0.000179	0.000615	CcSEcCtD
Tapentadol—Mental disorder—Methotrexate—lung cancer	0.000179	0.000615	CcSEcCtD
Tapentadol—Rash—Gemcitabine—lung cancer	0.000179	0.000615	CcSEcCtD
Tapentadol—Dermatitis—Gemcitabine—lung cancer	0.000179	0.000614	CcSEcCtD
Tapentadol—Hypersensitivity—Etoposide—lung cancer	0.000178	0.000613	CcSEcCtD
Tapentadol—Malnutrition—Methotrexate—lung cancer	0.000178	0.000611	CcSEcCtD
Tapentadol—Headache—Gemcitabine—lung cancer	0.000178	0.000611	CcSEcCtD
Tapentadol—Dyspepsia—Docetaxel—lung cancer	0.000177	0.000609	CcSEcCtD
Tapentadol—Hypoaesthesia—Doxorubicin—lung cancer	0.000176	0.000605	CcSEcCtD
Tapentadol—Decreased appetite—Docetaxel—lung cancer	0.000175	0.000602	CcSEcCtD
Tapentadol—Hypersensitivity—Paclitaxel—lung cancer	0.000175	0.000602	CcSEcCtD
Tapentadol—Urinary tract disorder—Doxorubicin—lung cancer	0.000175	0.0006	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Docetaxel—lung cancer	0.000174	0.000597	CcSEcCtD
Tapentadol—Asthenia—Etoposide—lung cancer	0.000174	0.000597	CcSEcCtD
Tapentadol—Connective tissue disorder—Doxorubicin—lung cancer	0.000174	0.000597	CcSEcCtD
Tapentadol—Fatigue—Docetaxel—lung cancer	0.000173	0.000597	CcSEcCtD
Tapentadol—Urethral disorder—Doxorubicin—lung cancer	0.000173	0.000596	CcSEcCtD
Tapentadol—Nausea—Irinotecan—lung cancer	0.000173	0.000595	CcSEcCtD
Tapentadol—Constipation—Docetaxel—lung cancer	0.000172	0.000592	CcSEcCtD
Tapentadol—Pruritus—Etoposide—lung cancer	0.000171	0.000589	CcSEcCtD
Tapentadol—Visual impairment—Doxorubicin—lung cancer	0.00017	0.000586	CcSEcCtD
Tapentadol—Asthenia—Paclitaxel—lung cancer	0.00017	0.000586	CcSEcCtD
Tapentadol—Nausea—Gemcitabine—lung cancer	0.000168	0.000579	CcSEcCtD
Tapentadol—Vomiting—Cisplatin—lung cancer	0.000168	0.000578	CcSEcCtD
Tapentadol—Pruritus—Paclitaxel—lung cancer	0.000168	0.000578	CcSEcCtD
Tapentadol—Vision blurred—Methotrexate—lung cancer	0.000167	0.000576	CcSEcCtD
Tapentadol—Rash—Cisplatin—lung cancer	0.000167	0.000573	CcSEcCtD
Tapentadol—Dermatitis—Cisplatin—lung cancer	0.000166	0.000573	CcSEcCtD
Tapentadol—Feeling abnormal—Docetaxel—lung cancer	0.000166	0.00057	CcSEcCtD
Tapentadol—Diarrhoea—Etoposide—lung cancer	0.000166	0.00057	CcSEcCtD
Tapentadol—Eye disorder—Doxorubicin—lung cancer	0.000165	0.000568	CcSEcCtD
Tapentadol—Cardiac disorder—Doxorubicin—lung cancer	0.000164	0.000564	CcSEcCtD
Tapentadol—Diarrhoea—Paclitaxel—lung cancer	0.000162	0.000559	CcSEcCtD
Tapentadol—Angiopathy—Doxorubicin—lung cancer	0.00016	0.000552	CcSEcCtD
Tapentadol—Dizziness—Etoposide—lung cancer	0.00016	0.000551	CcSEcCtD
Tapentadol—Immune system disorder—Doxorubicin—lung cancer	0.00016	0.000549	CcSEcCtD
Tapentadol—Vertigo—Methotrexate—lung cancer	0.00016	0.000549	CcSEcCtD
Tapentadol—Mediastinal disorder—Doxorubicin—lung cancer	0.000159	0.000548	CcSEcCtD
Tapentadol—Chills—Doxorubicin—lung cancer	0.000159	0.000545	CcSEcCtD
Tapentadol—Dizziness—Paclitaxel—lung cancer	0.000157	0.00054	CcSEcCtD
Tapentadol—Nausea—Cisplatin—lung cancer	0.000157	0.00054	CcSEcCtD
Tapentadol—Cough—Methotrexate—lung cancer	0.000155	0.000533	CcSEcCtD
Tapentadol—Mental disorder—Doxorubicin—lung cancer	0.000155	0.000533	CcSEcCtD
Tapentadol—Convulsion—Methotrexate—lung cancer	0.000154	0.000529	CcSEcCtD
Tapentadol—Vomiting—Etoposide—lung cancer	0.000154	0.000529	CcSEcCtD
Tapentadol—Malnutrition—Doxorubicin—lung cancer	0.000154	0.000529	CcSEcCtD
Tapentadol—Rash—Etoposide—lung cancer	0.000153	0.000525	CcSEcCtD
Tapentadol—Dermatitis—Etoposide—lung cancer	0.000152	0.000525	CcSEcCtD
Tapentadol—Headache—Etoposide—lung cancer	0.000152	0.000522	CcSEcCtD
Tapentadol—Arthralgia—Methotrexate—lung cancer	0.000151	0.00052	CcSEcCtD
Tapentadol—Tension—Doxorubicin—lung cancer	0.000151	0.000519	CcSEcCtD
Tapentadol—Vomiting—Paclitaxel—lung cancer	0.000151	0.000519	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.00015	0.000517	CcSEcCtD
Tapentadol—Rash—Paclitaxel—lung cancer	0.00015	0.000515	CcSEcCtD
Tapentadol—Dermatitis—Paclitaxel—lung cancer	0.00015	0.000514	CcSEcCtD
Tapentadol—Nervousness—Doxorubicin—lung cancer	0.000149	0.000514	CcSEcCtD
Tapentadol—Headache—Paclitaxel—lung cancer	0.000149	0.000511	CcSEcCtD
Tapentadol—Hypersensitivity—Docetaxel—lung cancer	0.000148	0.00051	CcSEcCtD
Tapentadol—Confusional state—Methotrexate—lung cancer	0.000146	0.000503	CcSEcCtD
Tapentadol—Anaphylactic shock—Methotrexate—lung cancer	0.000145	0.000499	CcSEcCtD
Tapentadol—Vision blurred—Doxorubicin—lung cancer	0.000145	0.000499	CcSEcCtD
Tapentadol—Asthenia—Docetaxel—lung cancer	0.000144	0.000496	CcSEcCtD
Tapentadol—Infection—Methotrexate—lung cancer	0.000144	0.000495	CcSEcCtD
Tapentadol—Nausea—Etoposide—lung cancer	0.000144	0.000495	CcSEcCtD
Tapentadol—Pruritus—Docetaxel—lung cancer	0.000142	0.00049	CcSEcCtD
Tapentadol—Nervous system disorder—Methotrexate—lung cancer	0.000142	0.000489	CcSEcCtD
Tapentadol—Agitation—Doxorubicin—lung cancer	0.000141	0.000486	CcSEcCtD
Tapentadol—Nausea—Paclitaxel—lung cancer	0.000141	0.000485	CcSEcCtD
Tapentadol—Skin disorder—Methotrexate—lung cancer	0.000141	0.000484	CcSEcCtD
Tapentadol—Hyperhidrosis—Methotrexate—lung cancer	0.00014	0.000482	CcSEcCtD
Tapentadol—Vertigo—Doxorubicin—lung cancer	0.000138	0.000475	CcSEcCtD
Tapentadol—Syncope—Doxorubicin—lung cancer	0.000138	0.000475	CcSEcCtD
Tapentadol—Diarrhoea—Docetaxel—lung cancer	0.000138	0.000473	CcSEcCtD
Tapentadol—Palpitations—Doxorubicin—lung cancer	0.000136	0.000468	CcSEcCtD
Tapentadol—Hypotension—Methotrexate—lung cancer	0.000135	0.000466	CcSEcCtD
Tapentadol—Loss of consciousness—Doxorubicin—lung cancer	0.000135	0.000465	CcSEcCtD
Tapentadol—Cough—Doxorubicin—lung cancer	0.000134	0.000462	CcSEcCtD
Tapentadol—Convulsion—Doxorubicin—lung cancer	0.000133	0.000458	CcSEcCtD
Tapentadol—Dizziness—Docetaxel—lung cancer	0.000133	0.000458	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000132	0.000454	CcSEcCtD
Tapentadol—Insomnia—Methotrexate—lung cancer	0.000131	0.000451	CcSEcCtD
Tapentadol—Arthralgia—Doxorubicin—lung cancer	0.000131	0.000451	CcSEcCtD
Tapentadol—Anxiety—Doxorubicin—lung cancer	0.000131	0.000449	CcSEcCtD
Tapentadol—Paraesthesia—Methotrexate—lung cancer	0.00013	0.000448	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.00013	0.000447	CcSEcCtD
Tapentadol—Dyspnoea—Methotrexate—lung cancer	0.000129	0.000445	CcSEcCtD
Tapentadol—Somnolence—Methotrexate—lung cancer	0.000129	0.000443	CcSEcCtD
Tapentadol—Dry mouth—Doxorubicin—lung cancer	0.000128	0.000441	CcSEcCtD
Tapentadol—Vomiting—Docetaxel—lung cancer	0.000128	0.00044	CcSEcCtD
Tapentadol—Dyspepsia—Methotrexate—lung cancer	0.000128	0.000439	CcSEcCtD
Tapentadol—Rash—Docetaxel—lung cancer	0.000127	0.000436	CcSEcCtD
Tapentadol—Dermatitis—Docetaxel—lung cancer	0.000127	0.000436	CcSEcCtD
Tapentadol—Confusional state—Doxorubicin—lung cancer	0.000127	0.000435	CcSEcCtD
Tapentadol—Decreased appetite—Methotrexate—lung cancer	0.000126	0.000434	CcSEcCtD
Tapentadol—Headache—Docetaxel—lung cancer	0.000126	0.000434	CcSEcCtD
Tapentadol—Anaphylactic shock—Doxorubicin—lung cancer	0.000126	0.000432	CcSEcCtD
Tapentadol—Oedema—Doxorubicin—lung cancer	0.000126	0.000432	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Methotrexate—lung cancer	0.000125	0.000431	CcSEcCtD
Tapentadol—Fatigue—Methotrexate—lung cancer	0.000125	0.00043	CcSEcCtD
Tapentadol—Infection—Doxorubicin—lung cancer	0.000125	0.000429	CcSEcCtD
Tapentadol—Shock—Doxorubicin—lung cancer	0.000124	0.000425	CcSEcCtD
Tapentadol—Nervous system disorder—Doxorubicin—lung cancer	0.000123	0.000424	CcSEcCtD
Tapentadol—Tachycardia—Doxorubicin—lung cancer	0.000123	0.000421	CcSEcCtD
Tapentadol—Skin disorder—Doxorubicin—lung cancer	0.000122	0.000419	CcSEcCtD
Tapentadol—Hyperhidrosis—Doxorubicin—lung cancer	0.000121	0.000418	CcSEcCtD
Tapentadol—Nausea—Docetaxel—lung cancer	0.00012	0.000411	CcSEcCtD
Tapentadol—Feeling abnormal—Methotrexate—lung cancer	0.000119	0.000411	CcSEcCtD
Tapentadol—Hypotension—Doxorubicin—lung cancer	0.000117	0.000404	CcSEcCtD
Tapentadol—Urticaria—Methotrexate—lung cancer	0.000115	0.000396	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000114	0.000393	CcSEcCtD
Tapentadol—Insomnia—Doxorubicin—lung cancer	0.000114	0.000391	CcSEcCtD
Tapentadol—Paraesthesia—Doxorubicin—lung cancer	0.000113	0.000388	CcSEcCtD
Tapentadol—Dyspnoea—Doxorubicin—lung cancer	0.000112	0.000385	CcSEcCtD
Tapentadol—Somnolence—Doxorubicin—lung cancer	0.000112	0.000384	CcSEcCtD
Tapentadol—Dyspepsia—Doxorubicin—lung cancer	0.000111	0.00038	CcSEcCtD
Tapentadol—Decreased appetite—Doxorubicin—lung cancer	0.000109	0.000375	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000108	0.000373	CcSEcCtD
Tapentadol—Fatigue—Doxorubicin—lung cancer	0.000108	0.000372	CcSEcCtD
Tapentadol—Constipation—Doxorubicin—lung cancer	0.000107	0.000369	CcSEcCtD
Tapentadol—Hypersensitivity—Methotrexate—lung cancer	0.000107	0.000367	CcSEcCtD
Tapentadol—Asthenia—Methotrexate—lung cancer	0.000104	0.000358	CcSEcCtD
Tapentadol—Feeling abnormal—Doxorubicin—lung cancer	0.000103	0.000356	CcSEcCtD
Tapentadol—Pruritus—Methotrexate—lung cancer	0.000103	0.000353	CcSEcCtD
Tapentadol—Urticaria—Doxorubicin—lung cancer	9.97e-05	0.000343	CcSEcCtD
Tapentadol—Diarrhoea—Methotrexate—lung cancer	9.92e-05	0.000341	CcSEcCtD
Tapentadol—Dizziness—Methotrexate—lung cancer	9.59e-05	0.00033	CcSEcCtD
Tapentadol—Hypersensitivity—Doxorubicin—lung cancer	9.25e-05	0.000318	CcSEcCtD
Tapentadol—Vomiting—Methotrexate—lung cancer	9.22e-05	0.000317	CcSEcCtD
Tapentadol—Rash—Methotrexate—lung cancer	9.14e-05	0.000314	CcSEcCtD
Tapentadol—Dermatitis—Methotrexate—lung cancer	9.13e-05	0.000314	CcSEcCtD
Tapentadol—Headache—Methotrexate—lung cancer	9.08e-05	0.000312	CcSEcCtD
Tapentadol—Asthenia—Doxorubicin—lung cancer	9.01e-05	0.00031	CcSEcCtD
Tapentadol—Pruritus—Doxorubicin—lung cancer	8.88e-05	0.000306	CcSEcCtD
Tapentadol—Nausea—Methotrexate—lung cancer	8.61e-05	0.000296	CcSEcCtD
Tapentadol—Diarrhoea—Doxorubicin—lung cancer	8.59e-05	0.000295	CcSEcCtD
Tapentadol—Dizziness—Doxorubicin—lung cancer	8.3e-05	0.000286	CcSEcCtD
Tapentadol—Vomiting—Doxorubicin—lung cancer	7.98e-05	0.000275	CcSEcCtD
Tapentadol—Rash—Doxorubicin—lung cancer	7.92e-05	0.000272	CcSEcCtD
Tapentadol—Dermatitis—Doxorubicin—lung cancer	7.91e-05	0.000272	CcSEcCtD
Tapentadol—Headache—Doxorubicin—lung cancer	7.87e-05	0.000271	CcSEcCtD
Tapentadol—Nausea—Doxorubicin—lung cancer	7.46e-05	0.000257	CcSEcCtD
Tapentadol—OPRK1—Signaling Pathways—KIT—lung cancer	1.5e-05	7.76e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CG—lung cancer	1.5e-05	7.76e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APC—lung cancer	1.5e-05	7.76e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—NRAS—lung cancer	1.5e-05	7.76e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	1.5e-05	7.72e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ADCY1—lung cancer	1.49e-05	7.71e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCG2—lung cancer	1.49e-05	7.71e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—lung cancer	1.49e-05	7.71e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGF—lung cancer	1.49e-05	7.67e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ADCY1—lung cancer	1.48e-05	7.64e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCG2—lung cancer	1.48e-05	7.64e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—POMC—lung cancer	1.48e-05	7.64e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—lung cancer	1.48e-05	7.62e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CB—lung cancer	1.47e-05	7.56e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO2—lung cancer	1.47e-05	7.56e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—HPGDS—lung cancer	1.47e-05	7.56e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGFR1—lung cancer	1.47e-05	7.56e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPP2R1B—lung cancer	1.46e-05	7.51e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—lung cancer	1.45e-05	7.5e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO2—lung cancer	1.45e-05	7.49e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—HPGDS—lung cancer	1.45e-05	7.49e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ENO1—lung cancer	1.45e-05	7.47e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPP2R1B—lung cancer	1.44e-05	7.45e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HIF1A—lung cancer	1.44e-05	7.45e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.44e-05	7.44e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—CREBBP—lung cancer	1.44e-05	7.44e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK3—lung cancer	1.44e-05	7.43e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—POMC—lung cancer	1.43e-05	7.39e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—lung cancer	1.42e-05	7.35e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.42e-05	7.35e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTT1—lung cancer	1.42e-05	7.33e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BRAF—lung cancer	1.41e-05	7.3e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTT1—lung cancer	1.41e-05	7.27e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2A6—lung cancer	1.41e-05	7.25e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GCLC—lung cancer	1.41e-05	7.25e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6R—lung cancer	1.4e-05	7.21e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CREBBP—lung cancer	1.4e-05	7.2e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2A6—lung cancer	1.39e-05	7.18e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GCLC—lung cancer	1.39e-05	7.18e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APOA1—lung cancer	1.39e-05	7.18e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	1.39e-05	7.16e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KDR—lung cancer	1.38e-05	7.12e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—lung cancer	1.37e-05	7.07e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CD—lung cancer	1.37e-05	7.05e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—lung cancer	1.36e-05	7e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MDM2—lung cancer	1.35e-05	6.97e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—lung cancer	1.35e-05	6.96e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—RAF1—lung cancer	1.35e-05	6.95e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—lung cancer	1.33e-05	6.87e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ENO1—lung cancer	1.33e-05	6.87e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAP2K1—lung cancer	1.33e-05	6.87e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CD—lung cancer	1.32e-05	6.82e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ENO1—lung cancer	1.32e-05	6.81e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	1.32e-05	6.79e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MTOR—lung cancer	1.31e-05	6.78e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CB—lung cancer	1.31e-05	6.78e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—lung cancer	1.31e-05	6.76e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP2E1—lung cancer	1.3e-05	6.7e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—lung cancer	1.3e-05	6.7e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—lung cancer	1.3e-05	6.68e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—NQO1—lung cancer	1.28e-05	6.62e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—lung cancer	1.27e-05	6.56e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APC—lung cancer	1.27e-05	6.56e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KIT—lung cancer	1.27e-05	6.56e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—NRAS—lung cancer	1.27e-05	6.56e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—lung cancer	1.27e-05	6.54e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—lung cancer	1.26e-05	6.52e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.26e-05	6.49e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGF—lung cancer	1.26e-05	6.48e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—lung cancer	1.26e-05	6.47e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.25e-05	6.43e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—lung cancer	1.22e-05	6.3e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—lung cancer	1.22e-05	6.28e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—POMC—lung cancer	1.21e-05	6.24e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—lung cancer	1.21e-05	6.24e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—EP300—lung cancer	1.21e-05	6.23e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—lung cancer	1.21e-05	6.23e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—lung cancer	1.2e-05	6.2e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—lung cancer	1.2e-05	6.17e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP2E1—lung cancer	1.19e-05	6.16e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CB—lung cancer	1.19e-05	6.15e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—lung cancer	1.19e-05	6.14e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MDM2—lung cancer	1.19e-05	6.11e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP2E1—lung cancer	1.18e-05	6.11e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—NQO1—lung cancer	1.18e-05	6.09e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—RAF1—lung cancer	1.18e-05	6.09e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6R—lung cancer	1.18e-05	6.09e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—lung cancer	1.18e-05	6.09e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CREBBP—lung cancer	1.18e-05	6.08e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—lung cancer	1.18e-05	6.07e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—JUN—lung cancer	1.17e-05	6.06e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—NQO1—lung cancer	1.17e-05	6.04e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—lung cancer	1.17e-05	6.03e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—lung cancer	1.16e-05	5.98e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—STK11—lung cancer	1.16e-05	5.97e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MTOR—lung cancer	1.15e-05	5.95e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CB—lung cancer	1.15e-05	5.95e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	1.15e-05	5.91e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—lung cancer	1.14e-05	5.89e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—lung cancer	1.14e-05	5.87e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	1.14e-05	5.86e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—lung cancer	1.14e-05	5.86e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAP2K1—lung cancer	1.13e-05	5.8e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CD—lung cancer	1.12e-05	5.77e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—lung cancer	1.11e-05	5.72e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—lung cancer	1.11e-05	5.71e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—lung cancer	1.11e-05	5.71e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—lung cancer	1.1e-05	5.68e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—lung cancer	1.09e-05	5.65e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—lung cancer	1.09e-05	5.61e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EP300—lung cancer	1.08e-05	5.59e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTP1—lung cancer	1.07e-05	5.53e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—lung cancer	1.07e-05	5.52e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—STK11—lung cancer	1.06e-05	5.49e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—lung cancer	1.06e-05	5.47e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—lung cancer	1.06e-05	5.46e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—STK11—lung cancer	1.06e-05	5.45e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—SRC—lung cancer	1.05e-05	5.43e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—lung cancer	1.05e-05	5.43e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CAT—lung cancer	1.04e-05	5.38e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—lung cancer	1.04e-05	5.35e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—lung cancer	1.03e-05	5.32e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—JUN—lung cancer	1.03e-05	5.31e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—lung cancer	1.03e-05	5.31e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—lung cancer	1.03e-05	5.29e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—lung cancer	1.02e-05	5.24e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—lung cancer	1.01e-05	5.23e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NRAS—lung cancer	1.01e-05	5.23e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—lung cancer	1.01e-05	5.19e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—lung cancer	1e-05	5.17e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MDM2—lung cancer	1e-05	5.17e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—lung cancer	9.99e-06	5.15e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAF1—lung cancer	9.98e-06	5.15e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—lung cancer	9.96e-06	5.14e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—TYMS—lung cancer	9.96e-06	5.14e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—lung cancer	9.91e-06	5.11e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—lung cancer	9.87e-06	5.09e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTP1—lung cancer	9.85e-06	5.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GSTM1—lung cancer	9.84e-06	5.08e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—EP300—lung cancer	9.82e-06	5.07e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTP1—lung cancer	9.77e-06	5.04e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MTOR—lung cancer	9.74e-06	5.03e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CB—lung cancer	9.74e-06	5.03e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—lung cancer	9.72e-06	5.01e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—lung cancer	9.71e-06	5.01e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CAT—lung cancer	9.59e-06	4.95e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CAT—lung cancer	9.51e-06	4.9e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EP300—lung cancer	9.5e-06	4.9e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—lung cancer	9.45e-06	4.87e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—lung cancer	9.44e-06	4.87e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—lung cancer	9.36e-06	4.83e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1A1—lung cancer	9.33e-06	4.81e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—lung cancer	9.33e-06	4.81e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—lung cancer	9.3e-06	4.8e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ERCC2—lung cancer	9.26e-06	4.77e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—lung cancer	9.25e-06	4.77e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—SRC—lung cancer	9.24e-06	4.77e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—lung cancer	9.24e-06	4.76e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—TYMS—lung cancer	9.16e-06	4.72e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—TYMS—lung cancer	9.08e-06	4.68e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GSTM1—lung cancer	9.06e-06	4.67e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—lung cancer	9.05e-06	4.67e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—lung cancer	9e-06	4.64e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GSTM1—lung cancer	8.98e-06	4.63e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—lung cancer	8.96e-06	4.62e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—lung cancer	8.95e-06	4.62e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—lung cancer	8.94e-06	4.61e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—lung cancer	8.91e-06	4.6e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—lung cancer	8.9e-06	4.59e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NRAS—lung cancer	8.89e-06	4.58e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—lung cancer	8.73e-06	4.5e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—lung cancer	8.72e-06	4.5e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—JUN—lung cancer	8.71e-06	4.49e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1A1—lung cancer	8.58e-06	4.43e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ERCC2—lung cancer	8.51e-06	4.39e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—lung cancer	8.51e-06	4.39e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1A1—lung cancer	8.51e-06	4.39e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—lung cancer	8.47e-06	4.37e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ERCC2—lung cancer	8.44e-06	4.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—lung cancer	8.44e-06	4.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—lung cancer	8.42e-06	4.34e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—lung cancer	8.28e-06	4.27e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—lung cancer	8.22e-06	4.24e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—lung cancer	8.1e-06	4.18e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EP300—lung cancer	8.03e-06	4.14e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—lung cancer	8.02e-06	4.13e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—APOA1—lung cancer	8.01e-06	4.13e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SRC—lung cancer	7.81e-06	4.03e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—lung cancer	7.75e-06	4e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	7.67e-06	3.95e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—lung cancer	7.65e-06	3.95e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—lung cancer	7.61e-06	3.92e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—lung cancer	7.53e-06	3.88e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NRAS—lung cancer	7.51e-06	3.87e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—lung cancer	7.42e-06	3.82e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—APOA1—lung cancer	7.36e-06	3.8e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—lung cancer	7.31e-06	3.77e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—lung cancer	7.3e-06	3.77e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—APOA1—lung cancer	7.3e-06	3.77e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—lung cancer	7.27e-06	3.75e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—lung cancer	7.19e-06	3.71e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—lung cancer	7.1e-06	3.66e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—lung cancer	7.03e-06	3.63e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—lung cancer	7e-06	3.61e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	6.99e-06	3.61e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—POMC—lung cancer	6.96e-06	3.59e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—lung cancer	6.84e-06	3.53e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—lung cancer	6.8e-06	3.51e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CREBBP—lung cancer	6.78e-06	3.5e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—lung cancer	6.72e-06	3.47e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—lung cancer	6.67e-06	3.44e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—lung cancer	6.55e-06	3.38e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—lung cancer	6.5e-06	3.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—lung cancer	6.47e-06	3.33e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CD—lung cancer	6.43e-06	3.31e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—POMC—lung cancer	6.4e-06	3.3e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—POMC—lung cancer	6.34e-06	3.27e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—lung cancer	6.34e-06	3.27e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CREBBP—lung cancer	6.23e-06	3.22e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—lung cancer	6.22e-06	3.21e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CREBBP—lung cancer	6.18e-06	3.19e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—lung cancer	5.94e-06	3.06e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—lung cancer	5.94e-06	3.06e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CD—lung cancer	5.91e-06	3.05e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CD—lung cancer	5.86e-06	3.02e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—lung cancer	5.83e-06	3.01e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—lung cancer	5.78e-06	2.98e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—lung cancer	5.75e-06	2.96e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—lung cancer	5.74e-06	2.96e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CB—lung cancer	5.6e-06	2.89e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—lung cancer	5.55e-06	2.86e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—lung cancer	5.5e-06	2.83e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—lung cancer	5.26e-06	2.71e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CB—lung cancer	5.15e-06	2.66e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CB—lung cancer	5.11e-06	2.63e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—lung cancer	5.1e-06	2.63e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—lung cancer	5.06e-06	2.61e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—lung cancer	4.85e-06	2.5e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—lung cancer	4.84e-06	2.5e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—EP300—lung cancer	4.62e-06	2.38e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—lung cancer	4.45e-06	2.3e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—lung cancer	4.41e-06	2.28e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—EP300—lung cancer	4.25e-06	2.19e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—EP300—lung cancer	4.21e-06	2.17e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—lung cancer	3.41e-06	1.76e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—lung cancer	3.14e-06	1.62e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—lung cancer	3.11e-06	1.61e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—lung cancer	2.79e-06	1.44e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—lung cancer	2.57e-06	1.32e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—lung cancer	2.54e-06	1.31e-05	CbGpPWpGaD
